Rallybio

RLYBPhase 2

New Haven, United Statesrallybio.com

Rallybio is a clinical-stage biotech committed to transforming the lives of millions of patients with rare diseases by advancing innovative therapies in complement dysregulation and hematology. The company leverages a team with extensive drug development experience, having contributed to over 30 drug approvals, and maintains a global network of industry and academic partners. Its disciplined approach aims to translate scientific breakthroughs into life-changing treatments, with a lead C5 inhibitor program (RLYB116) in confirmatory PK/PD studies.

Market Cap

$46.9M

Focus

Biologics

RLYB · Stock Price

USD 8.8746.81 (-84.07%)

Historical price data

AI Company Overview

Technology Platform

Rallybio employs a disciplined drug development model leveraging a team with extensive experience in translating scientific breakthroughs into approved drugs, supported by a global network of industry and academic partners.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Anti-(integrin beta-3) human monoclonal antibody	Fetal and Neonatal Alloimmune Thrombocytopenia	Phase 2
RLYB116 for Injection	Hematologic Diseases	Phase 1

Opportunities

The primary growth opportunity lies in successfully developing RLYB116 as a best-in-class C5 inhibitor for complement-mediated diseases, a multi-billion dollar market.

Additional opportunities exist in expanding the pipeline within hematology and other rare disease areas through its network and development expertise.

Risk Factors

Key risks include clinical trial failures for its lead candidate, intense competition in the complement inhibitor space, dependence on raising additional capital as a pre-revenue company, and pipeline concentration risk with RLYB116 as the primary value driver.

Competitive Landscape

Rallybio faces significant competition in complement dysregulation from AstraZeneca's Alexion (Soliris, Ultomiris) and Apellis Pharmaceuticals, among others. Its differentiation strategy is based on developing a potentially superior C5 inhibitor and leveraging a highly experienced team with a track record of drug approvals.